These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32487659)

  • 41. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Matched-case comparison for the role of surgery in FIGO stage Ib1-IIa squamous cell carcinoma of cervix and suspicious para-aortic lymph node metastasis.
    Kim HS; Park NH; Wu HG; Cho JY; Chung HH; Kim JW; Song YS; Kim SH; Kang SB
    Ann Surg Oncol; 2009 Jan; 16(1):133-9. PubMed ID: 18979134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does postoperative prophylactic irradiation of para-aortic lymph nodes reduce the risk of recurrence in uterine cervical cancer with positive pelvic lymph nodes?
    Yoshida K; Kajiyama H; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Utsumi F; Niimi K; Suzuki S; Kikkawa F
    Int J Clin Oncol; 2019 May; 24(5):567-574. PubMed ID: 30612268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
    Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
    Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.
    Meng Q; Liu X; Wang W; Hou X; Lian X; Sun S; Yan J; Liu Z; Miao Z; Hu K; Zhang F
    Radiat Oncol; 2019 Dec; 14(1):228. PubMed ID: 31842919
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Para-aortic lymph node recurrence after curative radiotherapy for cervical cancer.
    Cho WK; Kim YI; Park W; Yang K; Kim H; Cha H
    Int J Gynecol Cancer; 2019 Sep; 29(7):1116-1120. PubMed ID: 31474588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience.
    Manders DB; Sims TT; Bailey A; Hwang L; Richardson DL; Miller DS; Kehoe SM; Albuquerque KV; Lea JS
    Am J Clin Oncol; 2018 Dec; 41(12):1225-1230. PubMed ID: 29782361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis.
    Jung J; Park G; Kim YS
    Anticancer Res; 2014 Aug; 34(8):4361-6. PubMed ID: 25075072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
    Mayadev J; Zamarin D; Deng W; Lankes H; O'Cearbhaill R; Aghajanian CA; Schilder R
    Int J Gynecol Cancer; 2020 May; 30(5):701-704. PubMed ID: 31871115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical relevance of addition of conventional treatment to concurrent chemoradiotherapy in patients with FIGO stage III-IV cervical cancer: a retrospective analysis of a Japanese cohort.
    Kurosu H; Todo Y; Yamada R; Minowa K; Tsuruta T; Minobe S; Nishiyama N; Kato H
    Jpn J Clin Oncol; 2022 Mar; 52(3):244-250. PubMed ID: 34891157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Extended-field intensity modulated radiation therapy and intra-cavitary brachytherapy combined with chemotherapy for stage Ib1-IVa cervical cancer with positive para-aortic lymph nodes].
    Ke GH; Huang X; Huang XW; Liu SP; Wu XH
    Zhonghua Fu Chan Ke Za Zhi; 2013 Sep; 48(9):649-53. PubMed ID: 24332129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic Extended-Field Irradiation for Patients With Cervical Cancer Treated With Concurrent Chemoradiotherapy: A Propensity-Score Matching Analysis.
    Wang W; Liu X; Meng Q; Zhang F; Hu K
    Int J Gynecol Cancer; 2018 Oct; 28(8):1584-1591. PubMed ID: 30153215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer.
    Lee J; Kim TH; Kim GE; Keum KC; Kim YB
    J Gynecol Oncol; 2016 Sep; 27(5):e52. PubMed ID: 27329200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers.
    Chantalat E; Vidal F; Leguevaque P; Lepage B; Mathevet P; Deslandres M; Motton S
    Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():118-22. PubMed ID: 26295788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report.
    Abali H; Eren OO; Erman M; Uner AH; Kose F; Guler N
    Int J Gynecol Cancer; 2003; 13(5):687-9. PubMed ID: 14675356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.